肠道微生物代谢物SCFAs对肺动脉高压作用的研究进展

doi:10.3969/j.issn.1004-583X.2025.03.015

摘要/Abstract

摘要：

肺动脉高压(pulmonary hypertension,PH)是一种以显著的肺血管重构和进行性肺血管负荷增加,最终导致右心室肥大和重塑的综合征,其发病机制尚未完全明确,但越来越多的证据表明,肺动脉高压(pulmonary hypertension,PH)不再是单纯的呼吸或循环系统疾病,肠道微生物菌群也在其中起着重要作用。随着肠道微生物及其代谢物短链脂肪酸(short chain fatty acids,SCFAs)对PH作用研究的深入,所谓“肠-脑轴(gut-brain axis)”正在被逐渐揭示,故认为肠道微生物菌群可以通过调节免疫应答来影响PH的发生和发展。本文从肺动脉内皮细胞、平滑肌细胞及成纤维细胞3个方面就SCFAs对PH的作用做一综述,旨在为后期有关肠道微生物和PH的相关性研究提供一些依据。

中图分类号:

R541.5

任怀静, 陶嘉楠, 王学红, 安琪. 肠道微生物代谢物SCFAs对肺动脉高压作用的研究进展[J]. 临床荟萃, 2025, 40(3): 275-280.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2025.03.015

https://lchc.magtechjournal.com/CN/Y2025/V40/I3/275

图/表 1

参考文献 49

[1]	Hassoun PM. Pulmonary arterial hypertension[J]. N Engl J Med, 2021, 385(25):2361-2376.
[2]	Condon DF, Nickel NP, Anderson R, et al. The 6th world symposium on pulmonary hypertension: What's old is new[J]. F1000Res, 2019,8.
[3]	Poch D, Mandel J. Pulmonary hypertension[J]. Ann Intern Med, 2021, 174(4):ITC49-ITC64. doi: 10.7326/AITC202104200 pmid: 33844574
[4]	Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Identification of the most accurate estimates from a systematic literature review[J]. Pulm Circ, 2021, 11(1):765570412.
[5]	劳耀贤, 谢锦程, 肖梦媛, 等. 肺动脉高压的药物治疗:从传统到前沿[J/OL]. 中华高血压杂志(中英文),1-9[2025-02-26]. http://kns.cnki.net/kcms/detail/11.5540.R.20240914.0843.002.html.
[6]	Kim S, Rigatto K, Gazzana MB, et al. Altered gut microbiome profile in patients with pulmonary arterial hypertension[J]. Hypertension, 2020, 75(4):1063-1071. doi: 10.1161/HYPERTENSIONAHA.119.14294 pmid: 32088998
[7]	Moutsoglou DM, Tatah J, Prisco SZ, et al. Pulmonary arterial hypertension patients have a proinflammatory gut microbiome and altered circulating microbial metabolites[J]. Am J Respir Crit Care Med, 2023, 207(6):740-756.
[8]	Karoor V, Strassheim D, Sullivan T, et al. The short-chain fatty acid butyrate attenuates pulmonary vascular remodeling and inflammation in hypoxia-Induced pulmonary hypertension[J]. Int J Mol Sci, 2021, 22(18): 9916.
[9]	Beam A, Clinger E, Hao L. Effect of diet and dietary components on the composition of the gut microbiota[J]. Nutrients, 2021, 13(8): 2795.
[10]	Backhed F, Roswall J, Peng Y, et al. Dynamics and stabilization of the human gut microbiome during the first year of life[J]. Cell Host Microbe, 2015, 17(5):690-703. doi: 10.1016/j.chom.2015.04.004 pmid: 25974306
[11]	Huang L, Zhang H, Liu Y, et al. The role of gut and airway microbiota in pulmonary arterial hypertension[J]. Front Microbiol, 2022, 13:929752.
[12]	Almeida A, Mitchell AL, Boland M, et al. A new genomic blueprint of the human gut microbiota[J]. Nature, 2019, 568(7753):499-504.
[13]	Liu BN, Liu XT, Liang ZH, et al. Gut microbiota in obesity[J]. World J Gastroenterol, 2021, 27(25):3837-3850.
[14]	Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes[J]. Nutrients, 2021, 14(1): 166.
[15]	Tsai HJ, Tsai WC, Hung WC, et al. Gut microbiota and subclinical cardiovascular disease in patients with type 2 diabetes mellitus[J]. Nutrients, 2021, 13(8):2679.
[16]	Sepich-Poore GD, Zitvogel L, Straussman R, et al. The microbiome and human cancer[J]. Science, 2021, 371(6536): eabc4552.
[17]	Cao C, Yue S, Lu A, et al. Host-gut microbiota metabolic interactions and their role in precision diagnosis and treatment of gastrointestinal cancers[J]. Pharmacol Res, 2024, 207:107321.
[18]	Hays KE, Pfaffinger JM, Ryznar R. The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease[J]. Gut Microbes, 2024, 16(1):2393270.
[19]	Facchin S, Bertin L, Bonazzi E, et al. Short-chain fatty acids and human health: From metabolic pathways to current therapeutic implications[J]. Life (Basel), 2024, 14(5):559.
[20]	Perler BK, Friedman ES, Wu GD. The role of the gut microbiota in the relationship between diet and human health[J]. Annu Rev Physiol, 2023, 85:449-468.
[21]	Liu P, Wang Y, Yang G, et al. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis[J]. Pharmacol Res, 2021, 165:105420.
[22]	AI MS, Malik SS, AI IM, et al. Free fatty acid receptors (FFARs) in adipose: Physiological role and therapeutic outlook[J]. Cells, 2022, 11(4):750.
[23]	Zhang L, Liu C, Jiang Q, et al. Butyrate in energy metabolism: There is still more to learn[J]. Trends Endocrinol Metab, 2021, 32(3):159-169.
[24]	Tan JK, Macia L, Mackay CR. Dietary fiber and SCFAs in the regulation of mucosal immunity[J]. J Allergy Clin Immunol, 2023, 151(2):361-370. doi: 10.1016/j.jaci.2022.11.007 pmid: 36543697
[25]	常开丽, 张灿, 卢祥婷, 等. 肠道菌群及其代谢物与肺动脉高压相关性的研究进展[J]. 重庆医科大学学报, 2024, 49(10):1039-1044.
[26]	Hu Y, Chi L, Kuebler WM, et al. Perivascular inflammation in pulmonary arterial hypertension[J]. Cells, 2020, 9(11):2338.
[27]	Kong C, Chen X. Combined photodynamic and photothermal therapy and immunotherapy for cancer treatment: A review[J]. Int J Nanomedicine, 2022, 17:6427-6446.
[28]	Safaie QE, Stewart DJ. Cellular senescence in the pathogenesis of pulmonary arterial hypertension: The good, the bad and the uncertain[J]. Front Immunol, 2024, 15:1403669.
[29]	Li M, van Esch B, Wagenaar G, et al. Pro-and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells[J]. Eur J Pharmacol, 2018, 831:52-59.
[30]	Robles-Vera I, Toral M, de la Visitacion N, et al. Protective effects of short-chain fatty acids on endothelial dysfunction induced by angiotensin Ⅱ[J]. Front Physiol, 2020, 11:277. doi: 10.3389/fphys.2020.00277 pmid: 32372967
[31]	Li M, van Esch B, Henricks P, et al. Time and concentration dependent effects of short chain fatty acids on lipopolysaccharide-or tumor necrosis factor alpha-induced endothelial activation[J]. Front Pharmacol, 2018, 9:233.
[32]	Chelladurai P, Boucherat O, Stenmark K, et al. Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy[J]. Br J Pharmacol, 2021, 178(1):54-71.
[33]	Jiang Y, Song S, Liu J, et al. Epigenetic regulation of programmed cell death in hypoxia-induced pulmonary arterial hypertension[J]. Front Immunol, 2023, 14:1206452.
[34]	Chen F, Li X, Aquadro E, et al. Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension[J]. Free Radic Biol Med, 2016, 99:167-178.
[35]	Lecce L, Xu Y, V'Gangula B, et al. Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype[J]. J Clin Invest, 2021, 131(15): e131178.
[36]	Lechartier B, Berrebeh N, Huertas A, et al. Phenotypic diversity of vascular smooth muscle cells in pulmonary arterial hypertension: implications for therapy[J]. Chest, 2022, 161(1):219-231.
[37]	Donadon M, Santoro MM. The origin and mechanisms of smooth muscle cell development in vertebrates[J]. Development, 2021, 148(7):dev197384.
[38]	Roostalu U, Aldeiri B, Albertini A, et al. Distinct cellular mechanisms underlie smooth muscle turnover in vascular development and repair[J]. Circ Res, 2018, 122(2):267-281. doi: 10.1161/CIRCRESAHA.117.312111 pmid: 29167274
[39]	Gao Y, Yao Q, Meng L, et al. Double-side role of short chain fatty acids on host health via the gut-organ axes[J]. Anim Nutr, 2024, 18:322-339. doi: 10.1016/j.aninu.2024.05.001 pmid: 39290857
[40]	Tan X, Feng L, Huang X, et al. Histone deacetylase inhibitors promote eNOS expression in vascular smooth muscle cells and suppress hypoxia-induced cell growth[J]. J Cell Mol Med, 2017, 21(9):2022-2035. doi: 10.1111/jcmm.13122 pmid: 28266122
[41]	Zhong H, Yu H, Chen J, et al. The short-chain fatty acid butyrate accelerates vascular calcification via regulation of histone deacetylases and NF-kappaB signaling[J]. Vascul Pharmacol, 2022, 146:107096.
[42]	Mizuta K, Sasaki H, Zhang Y, et al. The short-chain free fatty acid receptor FFAR3 is expressed and potentiates contraction in human airway smooth muscle[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 318(6):L1248-L1260.
[43]	王淑美, 刘雅欣, 赵一桐, 等. 高同型半胱氨酸血症对心血管病进程的加速作用[J]. 生理科学进展, 2024, 55(3):248-256.
[44]	Ye Y, Xu Q, Wuren T. Inflammation and immunity in the pathogenesis of hypoxic pulmonary hypertension[J]. Front Immunol, 2023, 14:1162556.
[45]	Cussac LA, Cardouat G, Tiruchellvam PN, et al. TRPV4 channel mediates adventitial fibroblast activation and adventitial remodeling in pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 318(1):L135-L146.
[46]	储国俊. MicroRNA-26a-5p通过抑制自噬减轻肺血管重构的机制研究[D]. 上海: 中国人民解放军海军军医大学, 2023.
[47]	Castro PR, Bittencourt L, Larochelle S, et al. GPR43 regulates sodium butyrate-induced angiogenesis and matrix remodeling[J]. Am J Physiol Heart Circ Physiol, 2021, 320(3):H1066-H1079.
[48]	Oliveira AC, Yang T, Li J, et al. Fecal matter transplant from Ace2 overexpressing mice counteracts chronic hypoxia-induced pulmonary hypertension[J]. Pulm Circ, 2022, 12(1):e12015.
[49]	Moutsoglou DM. 2021 American thoracic society BEAR cage winning proposal: Microbiome transplant in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2022, 205(1):13-16.

细胞类型	SCFAs受体/靶点分布	SCFAs主要作用	主要参考文献
PAECs	GPR41/43?HDAC	抗炎作用;降低血管内皮细胞通透性;减轻氧化应激;抑制EMT等	Li等^[31];Karoor等^[8];Robles-Vera等^[30];Chen等^[34];Lecce等^[35]
PASMCs	GPR41/GPR109A?HDAC	抑制PASMCs的增殖和迁移(通过抑制PI3K-Akt途径);活化eNOS,增加NO含量;加速VSMC钙化等	Roostalu等^[38];Tan等^[40];Zhong^[41]
PAFs	HDAC?GPR43?	抗炎作用;抗纤维化作用;促纤维化和血管生成	储国俊^[46];Castro等^[47]

细胞类型	SCFAs受体/靶点分布	SCFAs主要作用	主要参考文献
PAECs	GPR41/43?HDAC	抗炎作用;降低血管内皮细胞通透性;减轻氧化应激;抑制EMT等	Li等^[31];Karoor等^[8];Robles-Vera等^[30];Chen等^[34];Lecce等^[35]
PASMCs	GPR41/GPR109A?HDAC	抑制PASMCs的增殖和迁移(通过抑制PI3K-Akt途径);活化eNOS,增加NO含量;加速VSMC钙化等	Roostalu等^[38];Tan等^[40];Zhong^[41]
PAFs	HDAC?GPR43?	抗炎作用;抗纤维化作用;促纤维化和血管生成	储国俊^[46];Castro等^[47]

肠道微生物代谢物SCFAs对肺动脉高压作用的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 49

相关文章 15

编辑推荐

Metrics

本文评价

[1]	延天美, 吴亚楠, 梁鹏, 魏立民. 粪便微生物移植:肥胖患者减重的新方案[J]. 临床荟萃, 2024, 39(5): 455-459.
[2]	匡竞, 滕双芩, 申彤彤, 闫怡然, 申川, 王玮, 王亚东, 赵彩彦. 门脉性肺动脉高压研究进展[J]. 临床荟萃, 2024, 39(4): 352-356.
[3]	王淑亮, 苏永峰. 肠道菌群在2型糖尿病中的研究进展[J]. 临床荟萃, 2024, 39(3): 274-278.
[4]	王沁濡, 尹琴, 李娟, 甘洪玉. 中医药治疗慢性阻塞性肺疾病合并肺动脉高压的研究进展[J]. 临床荟萃, 2024, 39(2): 188-192.
[5]	张晓璐, 李红山. 自身免疫性肝炎发病机制研究进展——聚焦“肠道菌群与免疫系统相互作用”[J]. 临床荟萃, 2024, 39(2): 177-182.
[6]	王鑫, 张展, 刘铎, 谢萍. 铁缺乏与肺动脉高压相关性的研究进展[J]. 临床荟萃, 2023, 38(9): 838-844.
[7]	杨小雄, 杨帆, 魏小果. 肠-微生物群-肝轴与代谢相关脂肪性肝病的研究进展[J]. 临床荟萃, 2023, 38(6): 559-563.
[8]	王晶霞, 汤灵玲. 肠道微生物群疗法防治复发性艰难梭菌感染研究进展[J]. 临床荟萃, 2022, 37(8): 759-763.
[9]	杜菲, 李英. 老年糖尿病肾病患者肠道菌群失调的研究进展[J]. 临床荟萃, 2022, 37(2): 178-181.
[10]	杨燕, 王德峰. 肠道菌群在糖尿病治疗中的研究进展[J]. 临床荟萃, 2022, 37(10): 953-956.
[11]	安勤燕, 姜蓉, 康彬, 杜明, 周仁明, 赵洪娟, 段炜, 卢飞, 刘锦铭. 特发性肺动脉高压患者RDW、NT-ProBNP、BigET-1、HMGB1水平变化及临床意义[J]. 临床荟萃, 2021, 36(11): 1001-1004.
[12]	闫新望，刘瑞娟. 微生物群在癌症发展及治疗中的进展[J]. 临床荟萃, 2019, 34(8): 764-768.
[13]	郭蕊1, 韦祁山2，李雯彬3，朱慧1，于国伟1. 短链脂肪酸通过肠脑轴改善肥胖的研究进展[J]. 临床荟萃, 2019, 34(12): 1148-1152.
[14]	孙明文1，何凤珍2，岳红梅1. 呼出气一氧化氮在非哮喘肺部疾病应用进展[J]. 临床荟萃, 2017, 32(9): 816-818.
[15]	袁雅冬;宫小薇. 2013年呼吸病学新进展[J]. 临床荟萃, 2014, 29(3): 275-281.